title: Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
abstract: Biodistribution studies demonstrate that intralesional administration of radiolabeled IgM results in high retention of radioactivity with little normal tissue uptake. This study examines the therapeutic potential of this modality.
  
  
  METHODS
  Nude mice bearing subcutaneous human head and neck squamous cell carcinoma xenografts were treated with single intralesional (IL) injections of tumor-reactive human monoclonal IgM (CR4E8) labeled with 25-394 microCi of yttrium-90 (90Y). Untreated mice, mice treated with IL unlabeled immunoconjugate or IL 90Y-aggregate, 160-400 microCi, served as controls. Mice were monitored for tumor growth and toxicity.
  
  
  RESULTS
  Mice received 80 Gy per 100 microCi of 90Y-labeled IgM and 110 Gy per 100 microCi of 90Y-aggregate. All tumors treated with 90Y-labeled IgM responded. In mice that received > or = 100 microCi, tumors macroscopically disappeared within three weeks from treatment with seventy-six percent tumor-free at 216 days. Acute toxicities associated with high activity 90Y-labeled IgM and 90Y-aggregate were moist skin desquamation and reduced blood counts. Late radiation damage to connective tissue was observed in mice treated with > 100 microCi of 90Y-labeled IgM.
  
  
  CONCLUSIONS
  Intralesional administration of 90Y-labeled IgM can ablate tumors in nude mice with modest acute or late toxicity. Further development of this modality for loco-regional therapy is warranted.
authors.affiliation: Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030.
authors.forename: Paul E
authors.initials: PE
authors.lastname: Borchardt
authors.forename: Huibert M
authors.initials: HM
authors.lastname: Vriesendorp
authors.forename: Ralph S
authors.initials: RS
authors.lastname: Freedman
authors.forename: Syed M
authors.initials: SM
authors.lastname: Quadri
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D001772:Blood Cell Count; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000532:radiotherapy; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000532:radiotherapy; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D007075:Immunoglobulin M / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D015552:Injections, Intralesional; D051379:Mice; D008819:Mice, Nude; D011786:Quality Control; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007075:Immunoglobulin M; D015021:Yttrium Radioisotopes